Structure-Based drug design for G protein-coupled receptors

Progress in Medicinal Chemistry

Volumn 53, Issue , 2014, Pages 1-63

  Congreve, Miles ^a   Dias, João M ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

Agonist; Antagonist; FBDD; Fragment; Fragment based drug design; GPCR; SBDD; Structure based drug design

Indexed keywords

ADENOSINE RECEPTOR; BETA ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; HISTAMINE RECEPTOR;

ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; PRIORITY JOURNAL; AGONISTS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG DISCOVERY; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, CXCR4; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; RECEPTORS, PURINERGIC P1;

EID: 84892401045     PISSN: 00796468     EISSN: 18757863     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63380-4.00001-9     Document Type: Chapter

References (164)

1. M.A. Hanson, and R.C. Stevens Discovery of new GPCR biology: one receptor structure at a time Structure 17 2009 8 14
2. M. Congreve, and F.H. Marshall The impact of GPCR structures on pharmacology and structure-based drug design Br J Pharmacol 159 5 2010 986 996
3. W. Liu, E. Chun, A.A. Thompson, P. Chubukov, F. Xu, and V. Katritch et al. Structural basis for allosteric regulation of GPCRs by sodium ions Science 337 6091 2012 232 236
4. K.A. Jacobson, and S. Costanzi New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors Mol Pharmacol 82 3 2012 361 371
5. V. Katritch, V. Cherezov, and R.C. Stevens Structure-function of the G protein-coupled receptor superfamily Annu Rev Pharmacol Toxicol 53 2013 531 556
6. J. Giraldo, and J. Pin G protein-coupled receptors 2011 RSC publishing Cambridge, UK
7. S. Granier, and B. Kobilka A new era of GPCR structural and chemical biology Nat Chem Biol 8 8 2012 670 673
8. D.J. Muller, N. Wu, and K. Palczewski Vertebrate membrane proteins: structure, function, and insights from biophysical approaches Pharmacol Rev 60 2008 43 78
9. S. Montaner, I. Kufareva, R. Abagyan, and J.S. Gutkind Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases Annu Rev Pharmacol Toxicol 53 2013 331 354
10. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat Rev Drug Discov 5 12 2006 993 996
11. J.A. Salon, D.T. Lodowski, and K. Palczewski The significance of G protein-coupled receptor crystallography for drug discovery Pharmacol Rev 63 2011 901 937
12. M.C. Lagerström, and H.B. Schiöth Structural diversity of G protein-coupled receptors and significance for drug discovery Nat Rev Drug Discov 7 2008 339 357
13. Thomson Reuters Integrity database, http://integrity.thomson-pharma.com/ integrity/xmlxsl/.
14. V. Katritch, V. Cherezov, and R.C. Stevens Diversity and modularity of G protein-coupled receptor structures Trends Pharmacol Sci 33 1 2012 17 27
15. M. Congreve, C.J. Langmead, J.S. Mason, and F.H. Marshall Progress in structure based drug design for G-protein-coupled receptors J Med Chem 54 13 2011 4283 4311
16. A.J. Harmar Family-B G-protein-coupled receptors Genome Biol 2 12 2001 reviews3013.1-reviews3013.10
17. F.Y. Siu, M. He, C. de Graaf, G.W. Han, D. Yang, and Z. Zhang et al. Structure of the class B human glucagon G protein coupled receptor Nature 499 7459 2013 444 449
18. K. Hollenstein, J. Kean, A. Bortolato, R.K.Y. Cheng, A.S. Doré, and A. Jazayeri et al. Structure of class B G-protein-coupled receptor corticotropin-releasing factor receptor 1 Nature 499 7459 2013 438 443
19. 2-adrenergic G protein-coupled receptor Science 318 5854 2007 1258 1265
20. D. Wacker, G. Fenalti, M.A. Brown, V. Katritch, R. Abagyan, and V. Cherezov et al. Conserved binding mode of human β2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography J Am Chem Soc 132 33 2010 11443 11445
21. 2 adrenergic receptor-Gs protein complex Nature 477 7366 2011 549 555
22. T. Warne, M.J. Serrano-Vega, J.G. Baker, R. Moukhametzianov, P.C. Edwards, and R. Henderson et al. Structure of a β1-adrenergic G-protein coupled receptor Nature 454 7203 2008 486 492
23. 1-adrenergic receptor Nature 469 7329 2011 241 244
24. T. Warne, P.C. Edwards, A.G.W. Leslie, and C.G. Tate Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol Structure 20 2012 841 849
25. F. Xu, H. Wu, V. Katritch, G.W. Han, K.A. Jacobson, and Z.G. Gao et al. Structure of an agonist-bound human A2A adenosine receptor Science 332 6027 2011 322 327
26. G. Lebon, T. Warne, P.C. Edwards, K. Bennett, C.J. Langmead, and A.G. Leslie et al. Agonist bound adenosine A2A receptor structures reveal common features of GPCR activation Nature 474 7352 2011 521 525
27. B. Wu, E.Y.T. Chien, C.D. Mol, G. Fenalti, W. Liu, and V. Katritch et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 6007 2010 1066 1071
28. E.Y.T. Chien, W. Liu, Q. Zhao, V. Katritch, G.W. Han, and M.A. Hanson et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist Science 330 6007 2010 1091 1095
29. T. Shimamura, M. Shiroishi, S. Weyand, H. Tsujimoto, G. Winter, and V. Katritch et al. Structure of the human histamine H1 receptor complex with doxepin Nature 475 7354 2011 65 70
30. K. Haga, A.C. Kruse, H. Asada, T. Yurugi-Kobayashi, M. Shiroishi, and C. Zhang et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist Nature 482 7386 2012 547 551
31. A.C. Kruse, J. Hu, A.C. Pan, D.H. Arlow, D.M. Rosenbaum, and E. Rosemond et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 482 7386 2012 552 559
32. S. Granier, A. Manglik, A.C. Kruse, T.S. Kobilka, F.S. Thian, and W.I. Weis et al. Structure of the δ-opioid receptor bound to naltrindole Nature 485 7398 2012 400 405
33. H. Wu, D. Wacker, M. Mileni, V. Katritch, G.W. Han, and E. Vardy et al. Structure of the human κ-opioid receptor in complex with JDTic Nature 485 7398 2012 327 332
34. A. Manglik, A.C. Kruse, T.S. Kobilka, F.S. Thian, J.M. Mathiesen, and R.K. Sunahara et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist Nature 485 7398 2012 321 326
35. A.A. Thompson, W. Liu, E. Chun, V. Katritch, H. Wu, and E. Vardy et al. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic Nature 485 7398 2012 395 401
36. M.A. Hanson, C.B. Roth, E. Jo, M.T. Griffith, F.L. Scott, and G. Reinhart et al. Crystal structure of a lipid G protein-coupled receptor Science 335 6070 2012 851 855
37. J.F. White, N. Noinaj, Y. Shibata, J. Love, B. Kloss, and F. Xu et al. Structure of the agonist-bound neurotensin receptor Nature 490 7421 2012 508 513
38. C. Zhang, Y. Srinivasan, D.H. Arlow, J.J. Fung, D. Palmer, and Y. Zheng et al. High-resolution crystal structure of human protease-activated receptor 1 Nature 492 7429 2012 387 392
39. C. Wang, Y. Jiang, J. Ma, H. Wu, D. Wacker, and V. Katritch et al. Structural basis for molecular recognition at serotonin receptors Science 340 6132 2013 610 614
40. D. Wacker, C. Wang, V. Katritch, G.W. Han, X.P. Huang, and E. Vardy et al. Structural features for functional selectivity at serotonin receptors Science 340 6132 2013 615 619
41. C. Wang, H. Wu, V. Katritch, G.W. Han, X.P. Huang, and W. Liu et al. Structure of the human smoothened receptor bound to an antitumour agent Nature 497 7449 2013 338 343
42. W.L. DeLano The PyMOL molecular graphics system 2002 DeLano Scientific San Carlos, CA http://www.PyMOL.org
43. T.K. Bjarnadóttir, R. Fredriksson, and H.B. Schiöth The adhesion GPCRs: a unique family of G protein-coupled receptors with important roles in both central and peripheral tissues Cell Mol Life Sci 64 16 2007 2104 2119
44. C.M. Niswender, and P.J. Conn Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu Rev Pharmacol Toxicol 50 2010 295 322
45. F. Gasparini, and W. Spooren Allosteric modulators for mGlu receptors Curr Neuropharmacol 5 3 2007 187 194
46. C.A. Gravius, M. Pietraszek, A. Dekundy, and W. Danyszt Metabotropic glutamate receptors as therapeutic targets for cognitive disorders Top Med Chem 10 2010 187 206
47. S. Urwyler Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol Rev 63 2011 59 126
48. G. Schulte, and V. Bryja The Frizzled family of unconventional G-protein-coupled receptors Trends Pharmacol Sci 28 10 2007 518 525
49. E. De Smaele, E. Ferretti, and A. Gulino Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers Curr Opin Investig Drugs 11 6 2010 707 718
50. P.W. Day, S.G.F. Rasmussen, C. Parnot, J.J. Fung, A. Masood, and T.S. Kobilka et al. A monoclonal antibody for G protein coupled receptor crystallography Nat Methods 4 2007 927 929
51. 2 adrenergic G-protein-coupled receptor Nature 450 7163 2007 383 387
52. 1-adrenergic receptor in a detergent-resistant form Proc Natl Acad Sci U S A 105 3 2008 877 882
53. Y. Shibata, J.F. White, M.J. Serrano-Vega, F. Magnani, A.L. Aloia, and R. Grisshammer et al. Thermostabilization of the neurotensin receptor NTS1 J Mol Biol 390 2 2009 262 277
54. 2a receptor Proc Natl Acad Sci U S A 105 31 2008 10744 10749
55. N. Robertson, A. Jazayeri, J. Errey, A. Baig, E. Hurrell, and A. Zhukov et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery Neuropharmacology 60 1 2011 36 44
56. M. Caffrey, and V. Cherezov Crystallizing membrane proteins using lipidic mesophases Nat Protoc 4 2009 706 731
57. M. Caffrey, D. Li, and A. Dukkipati Membrane protein structure determination using crystallography and lipidic mesophases: recent advances and successes Biochemistry 51 32 2012 6266 6288
58. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors Methods Neurosci 25 1995 366 428
59. V. Katritch, and R. Abagyan GPCR agonist binding revealed by modeling and crystallography Trends Pharmacol Sci 32 11 2011 637 643
60. J.S. Mason, A. Bortolato, M. Congreve, and F.H. Marshall New insights from structural biology into the druggability of G protein-coupled receptors Trends Pharmacol Sci 33 5 2012 249 260
61. C.G. Tate A crystal clear solution for determining G-protein-coupled receptor structures Trends Biochem Sci 37 9 2012 343 352
62. M. Kontoyianni, and Z. Liu Structure-based design in the GPCR target space Curr Med Chem 19 4 2012 544 556
63. M. Zhua, and M. Lia Revisiting the homology modeling of G-protein coupled receptors: β1-adrenoceptor as an example Mol BioSyst 8 2012 1686 1693
64. A.J. Venkatakrishnan, X. Deupi, G. Lebon, C.G. Tate, G.F. Schertler, and M.M. Babu Molecular signatures of G-protein-coupled receptors Nature 494 7436 2013 185 194
65. X. Deupi, and J. Standfuss Structural insights into agonist-induced activation of G-protein-coupled receptors Curr Opin Struct Biol 21 2011 541 551
66. D.M. Rosenbaum, S.G.F. Rasmussen, and B.K. Kobilka The structure and function of G-protein-coupled receptors Nature 459 7245 2009 356 363
67. M.M. Rosenkilde, T. Benned-Jensen, T.M. Frimurer, and T.W. Schwartz The minor binding pocket: a major player in 7TM receptor activation Trends Pharmacol Sci 31 2010 567 574
68. X. Deupi, J. Standfuss, and G. Schertler Conserved activation pathways in G-protein-coupled receptors Biochem Soc Trans 40 2012 383 388
69. E.C. Hulme GPCR activation: a mutagenic spotlight on crystal structures Trends Pharmacol Sci 34 1 2013 67 84
70. T. Kenakin Principles: receptor theory in pharmacology Trends Pharmacol Sci 25 4 2004 186 192
71. 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system Biochemistry 23 20 1984 4519 4525
72. J.H. Park, P. Scheerer, K.P. Hofmann, H.W. Choe, and O.P. Ernst Crystal structure of the ligand-free G-protein-coupled receptor opsin Nature 454 7201 2008 183 187
73. P. Scheerer, J.H. Park, P.W. Hildebrand, Y.J. Kim, N. Krauß, and H.W. Choe et al. Crystal structure of opsin in its G-protein-interacting conformation Nature 455 7212 2008 497 502
74. G. Lebon, T. Warne, and C.G. Tate Agonist-bound structures of G-protein-coupled receptors Curr Opin Struct Biol 22 4 2012 482 490
75. 2A receptor J Mol Biol 409 3 2011 298 310
76. 2 adrenoceptor Nature 469 7329 2011 175 180
77. B.L. Roth, and F.H. Marshall NOBEL 2012 chemistry: studies of a ubiquitous receptor family Nature 492 7427 2012 57
78. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine Structure 19 9 2011 1283 1293
79. 2A receptor define ligand efficacy Mol Pharmacol 83 5 2013 949 958
80. R.B. Rothman, and M.H. Baumann Serotonergic drugs and valvular heart disease Expert Opin Drug Saf 8 3 2009 317 329
81. E. Reiter, S. Ahn, A.K. Shukla, and R.J. Lefkowitz Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors Annu Rev Pharmacol Toxicol 52 2012 179 197
82. S.M. DeWire, D.S. Yamashita, D.H. Rominger, G. Liu, C.L. Cowan, and T.M. Graczyk et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J Pharmacol Exp Ther 344 3 2013 708 717
83. J.D. Tyndall, and R. Sandilya GPCR agonists and antagonists in the clinic J Med Chem 1 4 2005 405 421
84. J. Black Drugs from emasculated hormones: the principle of syntopic antagonism Science 245 4917 1989 486 493
85. P.P. Humphrey, W. Feniuk, M.J. Perren, H.E. Connor, and A.W. Oxford The pharmacology of the novel 5-HT1-like receptor agonist, GR43175 Cephalalgia 9 Suppl 9 1989 23 33
86. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision making in medicinal chemistry Nat Rev Drug Discov 6 2007 881 890
87. S. Bhavsar, S. Mudaliar, and A. Cherrington Evolution of exenatide as a diabetes therapeutic Curr Diabetes Rev 9 2 2013 161 193
88. L.M. Nørholk, J.J. Holst, and P.B. Jeppesen Treatment of adult short bowel syndrome patients with teduglutide Expert Opin Pharmacother 13 2 2012 235 243
89. S.K. Blick, S. Dhillon, and S.J. Keam Teriparatide: a review of its use in osteoporosis Drugs 68 18 2008 2709 2737
90. S. Dhillon Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy Drugs 71 8 2011 1071 1091
91. M. Congreve, C. Murray, and T. Blundell Structural biology and drug discovery Drug Discov Today 10 13 2005 895 907
92. D.C. Rees, M. Congreve, C.W. Murray, and R. Carr Fragment-based lead discovery Nat Rev Drug Discov 3 2004 660 672
93. M. Congreve, G. Chessari, D. Tisi, and A.J. Woodhead Recent developments in fragment-based drug discovery J Med Chem 51 13 2008 3661 3680
94. C.W. Murray, M.L. Verdonk, and D.C. Rees Experiences in fragment based drug discovery Trends Pharmacol Sci 33 5 2012 224 232
95. D.E. Scott, A.G. Coyne, S.A. Hudson, and C. Abell Fragment-based approaches in drug discovery and chemical biology Biochemistry 51 25 2012 4990 5003
96. R.M. Cooke, M. Koglin, J.C. Errey, and F.H. Marshall Preparation of purified GPCRs for structural studies Biochem Soc Trans 41 1 2013 185 190
97. 2A receptor with novel biological activity Chem Biol 7 12 2012 2064 2073
98. V. Cherezov, E. Abola, and R.C. Stevens Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets Methods Mol Biol 654 2010 141 168
99. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: a useful metric for lead selection Drug Discov Today 9 10 2004 430 431
100. N. Borshell, T. Papp, and M. Congreve Deal watch: valuation benefits of structure-enabled drug discovery Nat Rev Drug Discov 10 3 2011 166
101. D.A. Erlanson, R.S. McDowell, and T. O'Brien Fragment-based drug discovery J Med Chem 47 14 2004 3463 3482
102. H. Jhoti A new school for screening Nat Biotechnol 23 2005 184 186
103. M.N. Schulz, and R.E. Hubbard Recent progress in fragment-based lead discovery Curr Opin Pharmacol 9 2009 615 621
104. M. Baker Fragment-based lead discovery grows up Nat Rev Drug Discov 12 2013 5 7
105. 2A antagonists using structure based drug design J Med Chem 55 5 2012 1898 1903
106. 1 receptor agonists. WO2013072705, A1; 2013.
107. K.A. Jacobson Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates J Med Chem 56 10 2013 3749 3767
108. R.C. Stevens, V. Cherezov, V. Katritch, R. Abagyan, P. Kuhn, and H. Rosen et al. The GPCR network: a large-scale collaboration to determine human GPCR structure and function Nat Rev Drug Discov 12 2013 25 34
109. S. Costanzi Modeling G-protein-coupled receptors and their interactions with ligands Curr Opin Struct Biol 23 2 2012 185 190
110. B.K. Shoichet, and B.K. Kobilka Structure-based drug screening for G-protein-coupled receptors Trends Pharmacol Sci 33 5 2012 268 272
111. S. Costanzi Structure-based virtual screening for ligands of G protein-coupled receptors RSC Drug Discov Series 8 2011 359 374
112. 2A receptor MedChemComm 4 1 2013 52 67
113. 2-adrenergic receptor ligands Proc Natl Acad Sci U S A 106 16 2009 6843 6848
114. 2-adrenergic receptor for drug discovery Bioorg Med Chem Lett 18 5 2008 1598 1602
115. 2-adrenergic receptor for drug discovery Pt 2: identification of active compounds Bioorg Med Chem Lett 18 20 2008 5391 5395
116. 2 adrenergic receptor J Med Chem 51 16 2008 4978 4985
117. 2- adrenoceptor Bioorg Med Chem 20 2 2012 933 941
118. 2-adrenergic receptor: part 6 Bioorg Med Chem Lett 19 16 2009 4679 4683
119. 2-agonists Bioorg Med Chem Lett 21 13 2011 4027 4031
120. 1- Adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design J Med Chem 56 9 2013 3446 3455
121. 1 receptor J Med Chem 54 23 2010 8195 8206
122. 2A adenosine receptor bound to an antagonist Science 322 5905 2008 1211 1217
123. M. Michino, E. Abola, C.L. Brooks 3rd, J.S. Dixon, J. Moult, and R.C. Stevens Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 Nat Rev Drug Discov 8 6 2009 455 463
124. J. Carlsson, L. Yoo, Z.G. Gao, J.J. Irwin, B.K. Shoichet, and K.A. Jacobson Structure-based discovery of A2A adenosine receptor ligands J Med Chem 53 9 2010 3748 3755
125. 2A receptor antagonists J Med Chem 53 4 2010 1799 1809
126. 2A receptor ligands ChemMedChem 6 2011 2302 2311
127. 2A receptors: synthesis, pharmacology and structure-activity relationships Eur J Med Chem 54 2012 303 310
128. M.P.A. Sanders, L. Roumen, E. van der Horst, J.R. Lane, H.F. Vischer, and J. van Offenbeek et al. A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design J Med Chem 55 11 2012 5311 5325
129. G.J.P. van Westen, O.O. van den Hoven, R. van der Pijl, T. Mulder-Krieger, H. de Vries, and J.K. Wegner et al. Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data J Med Chem 55 16 2012 7010 7020
130. M. Congreve, R.L. Rich, D.G. Myszka, F. Figaroa, G. Siegal, and F.H. Marshall Fragment screening of stabilized G-protein-coupled receptors using biophysical methods Methods Enzymol 493 2011 115 136
131. C. Austin, S.N. Pettit, S.K. Magnolo, J. Sanvoisin, W. Chen, and S.P. Wood et al. Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitors J Biomol Screen 17 7 2012 868 876
132. Hughes D. Affinity capillary electrophoresis method for assessing biological interaction of a ligand/receptor pair such as a G protein coupled receptor and its targets as well as for drug screening. US Patent 20,120,175,255, A1; 2012.
133. 2A adenosine receptor crystallographic structure J Med Chem 52 10 2009 3284 3292
134. G. Pastorin, S. Federico, S. Paoletta, M. Corradino, F. Cateni, and B. Cacciari et al. Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process Bioorg Med Chem 18 7 2010 2524 2536
135. 2A adenosine receptor antagonists with improved water solubility J Med Chem 54 3 2011 877 889
136. 2A receptor Med Chem Lett 1 2010 160 164
137. J. Carlsson, D.K. Tosh, K. Phan, Z.G. Gao, and K.A. Jacobson Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists Med Chem Lett 3 9 2012 715 720
138. D. Catarzi, V. Colotta, F. Varano, D. Poli, L. Squarcialupi, and G. Filacchioni et al. Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies Bioorg Med Chem 21 1 2013 283 294
139. 3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin- 4-yl)acetamide scaffold Eur J Med Chem 59 2013 235 242
140. 3 receptor antagonists J Comput Aided Mol Des 26 11 2012 1247 1266
141. 3 adenosine receptor antagonists J Med Chem 54 2 2011 457 471
142. 3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition J Med Chem 52 23 2009 7640 7652
143. 3 adenosine receptor antagonists J Med Chem 55 22 2012 9654 9668
144. 3 adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition J Med Chem 53 8 2010 3361 3375
145. 3 adenosine receptor antagonists J Med Chem 54 14 2011 5205 5220
146. S. Taliani, I. Pugliesi, E. Barresi, F. Simorini, S. Salerno, and C. La Motta et al. 3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A2b adenosine receptor antagonists J Med Chem 55 4 2012 1490 1499
147. P. Kolb, K. Phan, Z.G. Gao, A.C. Marko, A. Sali, and K.A. Jacobson Limits of ligand selectivity from docking to models: in silico screening for A1 adenosine receptor antagonists PLoS ONE 7 11 2012 e49910
148. 3 adenosine receptor ligands based on chromone scaffold Biochem Pharmacol 84 2012 21 29
149. G.S. Inamdar, A.N. Pandya, H.M. Thakar, V. Sudarsanam, S. Kachler, and D. Sabbadin et al. New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides Eur J Med Chem 63 2013 924 934
150. 3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation J Med Chem 56 6 2013 2256 2269
151. 1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity J Med Chem 55 18 2012 8075 8090
152. D.K. Tosh, F. Deflorian, K. Phan, Z.G. Gao, T.C. Wan, and E. Gizewski et al. Structure-guided design of A3 adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions J Med Chem 55 10 2012 4847 4860
153. D.K. Tosh, K. Phan, Z.G. Gao, A.A. Gakh, F. Xu, and F. Deflorian et al. Optimization of adenosine 5′-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening J Med Chem 55 9 2012 4297 4308
154. 3 receptor agonists Bioorg Med Chem 18 22 2010 7923 7930
155. 3 adenosine receptor ligands J Med Chem 55 1 2012 342 356
156. 3 adenosine receptor ligands: combined 2-arylethynyl and bicyclohexane substitutions Med Chem Lett 3 2012 596 601
157. 2A adenosine receptor J Med Chem 55 1 2012 538 552
158. 2A receptor antagonists by virtual screening J Med Chem 55 5 2012 1904 1909
159. 2A receptor J Med Chem 54 13 2011 4312 4323
160. A.M. Fulton The chemokine receptors CXCR4 and CXCR3 in cancer Curr Oncol Rep 11 2009 125 131
161. E. Oberlin, A. Amara, B. Francoise, C. Bessia, J. Virelizier, and F. Arenzana-Seisdedos et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 Nature 382 6606 1996 833 835
162. J. Mungalpara, S. Thiele, ∅. Eriksen, J. Eksteen, M.M. Rosenkilde, and J. Våbenø Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4) J Med Chem 55 22 2012 10287 10291
163. T.L. Aboye, H. Ha, S. Majumder, F. Christ, Z. Debyser, and A. Shekhtman et al. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity J Med Chem 55 23 2012 10729 10734
164. Y. Yoshikawa, K. Kobayashi, S. Oishi, N. Fujii, and T. Furuya Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions Bioorg Med Chem Lett 22 6 2012 2146 2150